New MRD Assessment Data Using clonoSEQ® To Be Presented at 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

Read More

Browse our 650+ Publications​

Latest Publications

How I Use Next Generation Sequencing-MRD to Plan Approach and Prevent Relapse after HCT for Children and Adults with ALL

Muffly L, et al.
Blood
May 2024
Authors and Affiliates
Lori Muffly (Stanford University, United States) Emily Liang (Fred Hutchinson Cancer Center, United States) J. Dolan (Huntsman Cancer Institute/Intermountain Primary Chlldren's Hospital, Spencer Fox Eccles School of Medicine, University of Utah, United States) Michael Pulsipher (Huntsman Cancer Institute/Intermountain Primary Chlldren's Hospital, Spencer Fox Eccles School of Medicine, University of Utah., United States)

How I Use Next Generation Sequencing-MRD to Plan Approach and Prevent Relapseafter HCT for Children and Adults with ALL

Muffly L, et al.
Blood
May 2024
Authors and Affiliates
Lori Muffly, MD, MS1, Emily C. Liang, MD2, J. Gregory Dolan, MD3, Michael A. Pulsipher, MD3,4 1Department of Medicine, Division of Blood & Marrow Transplantation, Stanford University School of Medicine, Stanford, CA 2Department of Medicine, Division of Hematology & Oncology, University of Washington, Seattle, WA 3Intermountain Primary Children’s Hospital, Department of Pediatrics, Division of Pediatric Hematology/Oncology, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, UT 4Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, UT

Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial

O'Donnell E, et al.
Lancet Haematology
April 2024
Authors and Affiliates
Elizabeth O’Donnell, Clifton Mo, Andrew J Yee, Omar Nadeem, Jacob Laubach, Jacalyn Rosenblatt, Nikhil Munshi, Shonali Midha, Diana Cirstea, Pavlina Chrysafi, Nora Horick, Paul G Richardson, Noopur Raje Massachusetts General Hospital Cancer Center, Boston, MA, USA (E O’Donnell MD, A J Yee MD, D Cirstea MD, N Horick MS, Prof N Raje MD); Dana-Farber Cancer Institute, Boston, MA, USA (E O’Donnell, C Mo MD, O Nadeem MD, J Laubach MD, Prof N Munshi MD, S Midha MD, Prof P G Richardson MD); Beth Israel Deaconess Medical Center, Boston, MA, USA (J Rosenblatt MD); Mount Auburn Hospital, Cambridge, MA, USA (P Chrysafi MD); Harvard Medical School, Boston, MA, USA (E O’Donnell, C Mo, A J Yee, O Nadeem, J Laubach, J Rosenblatt, N Munshi, Prof S Midha, D Cirstea, P G Richardson, Prof N Raje)

Long-term follow-up of patients with follicular lymphoma using next generation sequencing to detect minimal residual disease

Clinical Lymphoma Myeloma & Leukemia
April 2024
Authors and Affiliates
Ayushi Chauhan2, Catherine Lai4 Frank Kuhr3, Heidi Simmons3, Bruce D. Cheson1 1- Center for Cancer and Blood Disorders, Bethesda, MD; 2- Medical College of Georgia, Augusta, Georgia; 3-Adaptive Biotechnologies, Seattle, WA; 4-University of Pennsylvania, Perelman Center for Advanced Medicine, Philadelphia, PA

CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results

Schultz L, et al.
Leukemia
March 2024
Authors and Affiliates
Liora M. Schultz1,2,6, Nikeshan Jeyakumar3,6, Anne Marijn Kramer 2, Bita Sahaf2, Hrishi Srinagesh3, Parveen Shiraz4, Neha Agarwal4, Mark Hamilton3, Courtney Erickson1, Ashley Jacobs1, Jennifer Moon1, Christina Baggott1, Sally Arai4, Sushma Bharadwaj4, Laura J. Johnston4, Michaela Liedtke3, Robert Lowsky4, Everett Meyer4, Robert Negrin4, Andrew Rezvani4, Judy Shizuru 4, Surbhi Sidana 4, Emily Egeler2, Sharon Mavroukakis2, Ramya Tunuguntla5, Nikolaos Gkitsas-Long5, Aidan Retherford5, Annie Kathleen Brown5, Anne-Louise Gramstrap-Petersen5, Raquel Martin Ibañez5, Steven A. Feldman2,5, David B. Miklos 2,4, Crystal L. Mackall 1,2, Kara L. Davis1,2, Matthew Frank2,4, Sneha Ramakrishna1,2 and Lori Muffly 2,4 1Division of Pediatric Hematology/Oncology, Stanford University, Stanford, CA, USA. 2Center for Cancer Cell Therapy, Stanford University, Stanford, CA, USA. 3Division of Hematology, Stanford University, Stanford, CA, USA. 4Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA. 5Laboratory for Cell and Gene Medicine, Stanford University, Stanford, CA, USA. 6These authors contributed equally: Liora M. Schultz, Nikeshan Jeyakumar. ✉email: lmuffly@stanford.edu

Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

Jabbour E, et al.
American Journal of Hematology
February 2024
Authors and Affiliates
Elias Jabbour1 | Gerhard Zugmaier2 | Vaibhav Agrawal3 | Pilar Martínez-Sánchez4 | José J. Rifon Roca5 | Ryan D. Cassaday6,7 | Boris Böll8 | Anita Rijneveld9 | Maher Abdul-Hay10 | Françoise Huguet11 | Thomas Cluzeau12 | Mar Tormo Díaz13 | Vladan Vucinic14 | José González-Campos15 | Alessandro Rambaldi16 | Stefan Schwartz17 | Céline Berthon18 | Jesús María Hernández-Rivas19,20,21 | Paul R. Gordon22 | Monika Brüggemann23 | Ali Hamidi22 | Yuqi Chen22 | Hansen L. Wong24 | Bharat Panwar22 | Yuliya Katlinskaya22 | Ana Markovic22 | Hagop Kantarjian1 1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 2Amgen Research (Munich), GmbH, Munich, Germany 3Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, California, USA 4Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain 5Hematology and Hemotherapy Department, Clínica Universidad de Navarra, Pamplona, Spain 6Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA 7Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA 8First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany 9Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands 10Perlmutter Cancer Center, New York University Langone Health, New York, New York, USA 11Department of Hematology, Institut Universitaire du Cancer-Oncopole CHU de Toulouse, Toulouse, France 12Université Nice Côte d'Azur, CHU de Nice, Nice, France 13Hematology Department, Hospital Clínico Universitario de Valencia, Instituto de Investigacion Sanitaria INCLIVA, Valencia, Spain 14Department of Hematology and Cell Therapy, University Hospital Leipzig, Leipzig, Germany 15Hematology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain 16Department of Oncology-Hematology, University of Milan, Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy 17Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt- Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany 18Centre Hospitalier Universitaire de Lille, Lille, France 19IBSAL, IBMCC, CSIC, Cancer Research Center, University of Salamanca, Salamanca, Spain 20Department of Hematology, University Hospital of Salamanca, Salamanca, Spain 21CIBERONC, Research Group CB16/12/00233, Salamanca, Spain 22Amgen Inc., Thousand Oaks, California, USA 23Department of Hematology, University of Schleswig-Holstein, Kiel, Germany 24Clinical Pharmacology, Modeling and Simulation, Amgen Inc., South San Francisco, California, USA

Isatuximab in combination with carfilzomib anddexamethasone in 1q21þ patients with relapsed/refractorymultiple myeloma: Long‐term outcomes in the Phase 3 IKEMA study

Facon T, et al.
hematological oncology
February 2024
Authors and Affiliates
Thierry Facon1 | Philippe Moreau2 | Ivan Špicka3 | Kenshi Suzuki4 | Kwee Yong5 | Joseph Mikhael6 | Taro Fukao7 | Kamlesh Bisht7 | Nicole M. Armstrong8 | Sandrine Macé9 | Marie‐Laure Risse10 | Thomas Martin11 1Department of Hematology, Lille University Hospital, Lille, France 2Department of Hematology, University Hospital Hôtel‐Dieu, Nantes, France 3Department of Hematology, 1st Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic 4Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center, Tokyo, Japan 5Department of Haematology, University College Hospital, London, UK 6Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, Arizona, USA 7Sanofi, Global Oncology, Cambridge, Massachusetts, USA 8Sanofi, Global Medical Affairs, Cambridge, Massachusetts, USA 9Sanofi, Research and Development, Chilly‐ Mazarin, France 10Sanofi, Research and Development, Vitry‐ Sur‐Seine, France 11University of California San Francisco Medical Center, San Francisco, California, USA

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

Stilgenbauer S, et al.
Blood Advances
January 2024
Authors and Affiliates
Stephan Stilgenbauer,1 Eugen Tausch,1 Andrew W. Roberts,2 Matthew S. Davids,3 Barbara Eichhorst,4 Michael Hallek,4 Peter Hillmen,5 Christof Schneider,1 Johannes Schetelig,6 Sebastian Böttcher,7 Arnon P. Kater,8 Yanwen Jiang,9 Michelle Boyer,9 Relja Popovic,10 Majd T. Ghanim,10 Michael Moran,10 Wendy J. Sinai,10 Xifeng Wang,10 Nabanita Mukherjee,10 Brenda Chyla,10 William G. Wierda,11,* John F. Seymour2,* 1Division of CLL, Internal Medicine III, Ulm University, Ulm, Germany; 2Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Australia; 3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 4Department of Internal Medicine, Center of Integrated Oncology Köln Bonn, University Hospital of Cologne, Cologne, Germany; 5Leeds Teaching Hospitals, NHS Trust, Leeds, United Kingdom; 6University Hospital, Technische Universität Dresden, Dresden, Germany; 7Division of Internal Medicine, Medical Clinic III-Hematology, Oncology and Palliative Medicine, Rostock University Medical Center, Rostock, Germany; 8Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands; 9Genentech, South San Francisco, CA; 10AbbVie Inc, North Chicago, IL; 11The University of Texas MD Anderson Cancer Center, Houston, TX *Contributed equally.

Daratumumab in Myeloma Patients With Early or Late Relapse After Initial Therapy: Subgroup Analysis of CASTOR and POLLUX.

Spencer A, et al.
Blood Advances
January 2024
Authors and Affiliates
Andrew Spencer, Philippe Moreau, M V Mateos, Hartmut Goldschmidt, Kenshi Suzuki, Mark-David Levin, Pieter Sonneveld, Robert Z Orlowski, Sung-Soo Yoon, Saad Z Usmani, Katja C Weisel, Donna Reece, Tahamtan Ahmadi, Huiling Pei, Wendy Garvin Mayo, Xue Gai, Jodi Carey, J Blake Bartlett, Robin Carson, Meletios-Athanasios A Dimopoulos